Goldhaber, S., Heit, J., Sharma, G.V., Nagel, J.S., Kim, D., Parker, J.A., Drum, D., Reagan, K., Anderson, J., Kessler, C. and Markis, J. (1988) Randomised Controlled Trial of Recombinant Tissue Plasminogen Activator Versus Urokinase in the Treatment of Acute Pulmonary Embolism. The Lancet, 332, 293-298.
https://doi.org/10.1016/S0140-6736(88)92354-9

has been cited by the following article:

• TITLE: Current Concepts in the Diagnosis and Management of Pulmonary Embolism

  AUTHORS: Sridhar Kasturi

  KEYWORDS: Pulmonary Embolism, Management of PE

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.12 No.3, March 30, 2021

  ABSTRACT: Acute pulmonary embolism (PE) is one of the most common causes of cardiovascular death. Most often acute PE is associated with under diagnosis, misdiagnosis and delay in diagnosis and management leading to high morbidity and mortality. PE outcomes will improve with proper evaluation of clinical symptoms and signs, relevant diagnostic tests, identifying high-risk patients suitable for early re-perfusion with I.V. or catheter-directed thrombolytic therapy or surgical embolectomy and in some cases additional use of mechanical circulatory support. During clinical evaluation modified Geneva score, Well’s score, and Simplified pulmonary embolism severity index (sPESI) scores are useful in assessing PE and its adverse outcomes. Hestia criteria are useful in identifying suitable for outpatient management of PE. Long-term management of PE involves identifying patients prone for recurrence and CTPE with appropriate long-term prophylaxis using oral anticoagulants.